European journal of neurology : the official journal of the European Federation of Neurological Societies
-
Randomized Controlled Trial Multicenter Study
Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine.
OnabotulinumtoxinA was effective and well tolerated for prophylaxis of headache in patients with chronic migraine (CM) in two randomized, double-blind, placebo-controlled, phase 3 trials. To further assess the safety and tolerability of onabotulinumtoxinA in CM prophylaxis in adults, the pooled safety data from four double-blind, placebo-controlled trials were analyzed. ⋯ Multiple treatments with onabotulinumtoxinA at doses of 75-260 U administered every 12 weeks, and up to five treatment cycles, were well tolerated for the prophylaxis of headache in adults with CM.